Literature DB >> 16301836

Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential.

Ian Zachary1.   

Abstract

Vascular endothelial growth factor (VEGF or VEGF-A) and its receptors play essential roles in the formation of blood vessels during embryogenesis and in disease. Most biological effects of VEGF are mediated via two receptor tyrosine kinases, VEGFR1 and VEGFR2, but specific VEGF isoforms also bind neuropilins (NP) 1 and 2, non-tyrosine kinase receptors originally identified as receptors for semaphorins, polypeptides with essential roles in neuronal patterning. There is abundant evidence that VEGF-A has neurotrophic and neuroprotective effects on neuronal and glial cells in culture and in vivo, and can stimulate the proliferation and survival of neural stem cells. VEGFR2 and NP1 are the major VEGF receptors expressed on neuronal cells and, while the mechanisms mediating neuroprotective effects of VEGF are not fully understood, VEGF stimulates several signalling events in neuronal cell types, including activation of phospholipase C-gamma, Akt and ERK. Findings in diverse models of nerve damage and disease suggest that VEGF has therapeutic potential as a neuroprotective factor. VEGF is a key mediator of the angiogenic response to cerebral and peripheral ischaemia, and promotes nerve repair following traumatic spinal injury. Recent work has revealed a role for reduced VEGF expression in the pathogenesis of amyotrophic lateral sclerosis, a rare neurodegenerative disease caused by selective loss of motor neurons. In many instances, the neuroprotective effects of VEGF appear to result from a combination of the indirect consequences of increased angiogenesis, and the direct stimulation of neuronal function. However, more work is required to determine the specific functional role of direct neuronal effects of VEGF. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301836     DOI: 10.1159/000088637

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  111 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

2.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.

Authors:  Michael I Dorrell; Edith Aguilar; Lea Scheppke; Faith H Barnett; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

3.  Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.

Authors:  Stephanie Debette; Sophie Visvikis-Siest; Ming-Huen Chen; Ndeye-Coumba Ndiaye; Ci Song; Anita Destefano; Radwan Safa; Mohsen Azimi Nezhad; Douglas Sawyer; Jean-Brice Marteau; Vanessa Xanthakis; Gerard Siest; Lisa Sullivan; Michele Pfister; Holly Smith; Seung-Hoan Choi; John Lamont; Lars Lind; Qiong Yang; Peter Fitzgerald; Erik Ingelsson; Ramachandran S Vasan; Sudha Seshadri
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

4.  Vascular endothelial cell growth factor-a: not just for endothelial cells anymore.

Authors:  Patricia A D'Amore
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 5.  Unexpected benefits of intermittent hypoxia: enhanced respiratory and nonrespiratory motor function.

Authors:  E A Dale; F Ben Mabrouk; G S Mitchell
Journal:  Physiology (Bethesda)       Date:  2014-01

6.  Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin.

Authors:  Hideki Hayashi; Robert B Campenot; Dennis E Vance; Jean E Vance
Journal:  J Biol Chem       Date:  2009-08-28       Impact factor: 5.157

7.  Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Authors:  Fernando Cruz-Gonzalez; Lucía Cabrillo-Estévez; Gloria López-Valverde; Clara Cieza-Borrella; Emiliano Hernández-Galilea; Rogelio González-Sarmiento
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-13       Impact factor: 3.117

8.  Altered hypoxia-inducible factor-1 alpha expression levels correlate with coronary vessel anomalies.

Authors:  Jamie Wikenheiser; Julie A Wolfram; Madhusudhana Gargesha; Ke Yang; Ganga Karunamuni; David L Wilson; Gregg L Semenza; Faton Agani; Steven A Fisher; Nicole Ward; Michiko Watanabe
Journal:  Dev Dyn       Date:  2009-10       Impact factor: 3.780

9.  VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.

Authors:  Renhai Cao; Yuan Xue; Eva-Maria Hedlund; Zhaodong Zhong; Katerina Tritsaris; Barbara Tondelli; Franco Lucchini; Zhenping Zhu; Steen Dissing; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

10.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.